tert-butyl (3-bromo-2,2-dimethyl-2H-chromen-7-yl)(methyl)carbamate | 1258974-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: tert-butyl (3-bromo-2,2-dimethyl-2H-chromen-7-yl)(methyl)carbamate
• CAS: 1258974-79-6
• 化学式: C₁₇H₂₂BrNO₃
• 分子量: 368.271
• InChiKey: RWRKHHZHWPDEFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.96
• 重原子数：
  22.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  38.77
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  乙烯基硼酸二丁酯 、 tert-butyl (3-bromo-2,2-dimethyl-2H-chromen-7-yl)(methyl)carbamate 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 18.0h， 生成 tert-butyl (2,2-dimethyl-3-vinyl-2H-chromen-7-yl)(methyl)carbamate
  参考文献：
  名称：

  Discovery of Novel Benzopyranyl Tetracycles that Act as Inhibitors of Osteoclastogenesis Induced by Receptor Activator of NF-κB Ligand

  摘要：

  A novel benzopyran-fused molecular framework 7ai was discovered as a specific inhibitor of RANKL-induced osteoclastogenesis using a cell-based TRAP activity assay from drug-like small-molecule libraries constructed by diversity-oriented synthesis. Its inhibitory activity was confirmed by in vitro evaluations including specific inhibition of RANKL-induced ERK phosphorylation and NF-kappa B transcriptional activation. 7ai can serve as a specific small-molecule modulator for mechanistic studies of RANKL-induced osteoclast differentiation as well as a potential lead for the development of antiresorptive drugs.

  DOI：

  10.1021/jm1011269
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 3-bromo-N,2,2-trimethylchromen-7-amine 以 二氯甲烷 为溶剂， 反应 96.0h， 以99.9%的产率得到tert-butyl (3-bromo-2,2-dimethyl-2H-chromen-7-yl)(methyl)carbamate
  参考文献：
  名称：

  Discovery of Novel Benzopyranyl Tetracycles that Act as Inhibitors of Osteoclastogenesis Induced by Receptor Activator of NF-κB Ligand

  摘要：

  A novel benzopyran-fused molecular framework 7ai was discovered as a specific inhibitor of RANKL-induced osteoclastogenesis using a cell-based TRAP activity assay from drug-like small-molecule libraries constructed by diversity-oriented synthesis. Its inhibitory activity was confirmed by in vitro evaluations including specific inhibition of RANKL-induced ERK phosphorylation and NF-kappa B transcriptional activation. 7ai can serve as a specific small-molecule modulator for mechanistic studies of RANKL-induced osteoclast differentiation as well as a potential lead for the development of antiresorptive drugs.

  DOI：

  10.1021/jm1011269